GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Bioage Labs Inc (NAS:BIOA) » Definitions » Notes Receivable

BIOA (Bioage Labs) Notes Receivable : $0.00 Mil (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Bioage Labs Notes Receivable?

Bioage Labs's Notes Receivable for the quarter that ended in Dec. 2024 was $0.00 Mil.


Bioage Labs Notes Receivable Historical Data

The historical data trend for Bioage Labs's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioage Labs Notes Receivable Chart

Bioage Labs Annual Data
Trend Dec22 Dec23 Dec24
Notes Receivable
- - -

Bioage Labs Quarterly Data
Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Notes Receivable Get a 7-Day Free Trial Premium Member Only - - - - -

Bioage Labs Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Bioage Labs Notes Receivable Related Terms

Thank you for viewing the detailed overview of Bioage Labs's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Bioage Labs Business Description

Traded in Other Exchanges
Address
1445A South 50th Street, Richmond, CA, USA, 94804
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. The pipeline Products of the company are NLRP3 inhibitors, APJ against, and others.

Bioage Labs Headlines

From GuruFocus